Dr Pavan Ganapati Bhat resigns as Director & Executive Vice President (Technical Operations) of Natco Pharma

Telangana: Natco Pharma has announced the resignation of Dr Pavan Ganapati Bhat as Director & Executive Vice President (Technical Operations) of the Company due to new career opportunity outside the Company.

Dr Pavan joined Natco Pharma in 2016 as Executive Vice President - Technical Operations. Prior to his tenure at Natco, he worked at Mylan in the USA, focusing on Transdermal R&D, 050 R&D, and Corporate & Business Development.

Read also: Natco Pharma appoints Madhava Rao Karicherla as Associate Vice President - Formulation RnD, Pharma Division, Kothur Unit

NATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company’s manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.

Read also: Natco Pharma gets approval for Everolimus tablets for Oral Suspension for subependymal giant cell astrocytoma